SCHEMBL5135495

SCHEMBL5135495

CCCCn1c(-c2ccccc2)nc(-c2ccccc2)c1CN(Cc1ccc(OC)cc1)Cc1c(OC)cc(OC)cc1OC

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.43
CD274 Q9NZQ7 1/20 0.38
TSHR P16473 4/20 0.37
ALDH1A1 P00352 4/20 0.37
GAA P10253 3/20 0.37
KDM4E B2RXH2 3/20 0.37
LMNA P02545 2/20 0.37
NPSR1 Q6W5P4 2/20 0.37
CRHR1 P34998 1/20 0.37
SMN1; SMN2 Q16637 4/20 0.36
TP53 P04637 3/20 0.36
PDE5A O76074 1/20 0.36
BCHE P06276 3/20 0.36
HSD17B10 Q99714 1/20 0.36
MAPT P10636 2/20 0.36
HTT P42858 2/20 0.35
CNR2 P34972 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
PDE4B Q07343 1/20 0.35
CASR P41180 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5137023 0.96 C5AR1 (0.42) C5AR1CD274TSHRALDH1A1GAA
SCHEMBL651365 0.92 C5AR1 (0.46) C5AR1TSHRALDH1A1GAAKDM4E
SCHEMBL5072205 0.91 C5AR1 (0.46) C5AR1TSHRALDH1A1GAAKDM4E
SCHEMBL5134872 0.90 C5AR1 (0.44) C5AR1TSHRALDH1A1GAAKDM4E
SCHEMBL5135242 0.90 C5AR1 (0.45) C5AR1TSHRALDH1A1GAAKDM4E
SCHEMBL5136939 0.90 CRHR1 (0.42) C5AR1TSHRALDH1A1GAAKDM4E
SCHEMBL5136291 0.90 C5AR1 (0.45) C5AR1TSHRALDH1A1GAAKDM4E
SCHEMBL5136856 0.89 C5AR1 (0.45) C5AR1TSHRALDH1A1GAAKDM4E
SCHEMBL5136185 0.89 C5AR1 (0.44) C5AR1TSHRALDH1A1GAAKDM4E
SCHEMBL5134952 0.89 C5AR1 (0.44) C5AR1TSHRALDH1A1GAAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed